<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="epcart-ctdna-epcor-dowling-ps1912">
    <meta name="study:title" content="PS1912 - ctDNA-directed Epcoritamab in post-CAR-T LBCL (EpLCART)">
    <meta name="study:fileName" content="Abstracts/PS1912-EpLCART-ctDNA-Epcor-Dowling.html">
    <meta name="study:cancerTypes" content="LBCL,DLBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="3L+">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Epcoritamab,Bispecific antibodies,Lenalidomide,Immunomodulatory drugs,Rituximab,Monoclonal Antibody,CAR-T cell therapy">

    <title>PS1912: ctDNA-Directed Epcoritamab in Post-CAR-T LBCL (Dowling) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PS1912 - ctDNA-Directed Epcoritamab Post-CAR-T in High-Risk LBCL (EpLCART Prelim.)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=10 Enrolled)</h4>
                    <p>R/R LBCL Pts, MRD+ post CAR-T (D+25-D+100). Aim: Evaluate Epcoritamab ± R2 to prevent progression.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 64 64" fill="var(--sobi-teal)">
                        <path d="M32 60 V40 M20 40 L32 40 L44 40 M20 40 L12 28 L4 20 M44 40 L52 28 L60 20 M12 28 L16 24 M52 28 L48 24" stroke="var(--sobi-teal)" stroke-width="5" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
                        <circle cx="4" cy="20" r="3" fill="var(--sobi-orange)"/><circle cx="60" cy="20" r="3" fill="var(--sobi-yellow)"/>
                    </svg>
                    <h4>Intervention</h4>
                    <p>6 cycles Epcoritamab alone or + Lenalidomide + Rituximab (Epcor-R2) for MRD+ pts.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (Interim, N=10)</h4>
                    <p>MRD Negativity Post C2: <span class="highlight-value">80% (8/10)</span>.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Well-tolerated. No G>1 CRS/ICANS. G3/4 Neutro 60%, Thrombo 40%. Feasible with encouraging MRD response.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PS1912 - Circulating tumour DNA-directed intervention with Epcoritamab alone or in combination with Lenalidomide and Rituximab is feasible in the early post-CAR-T population at high risk of relapse: Preliminary data from EpLCART</h1>
            <p class="abstract-sub-header">Mark Dowling, Shafqat Inam, Hamish Scott, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PS1912 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Half or more patients treated with anti-CD19 CAR T-cell therapy for R/R LBCL do not experience durable remissions.</li>
                        <li>Monitoring ctDNA for MRD has prognostic value in LBCL post-CAR T.</li>
                        <li>Patients with MRD+ status post-CAR T (despite radiologic response) are at high risk of progression.</li>
                        <li>CD20xCD3 BsAbs can induce durable remissions in patients post-CAR T progression.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To hypothesize that BsAb (epcoritamab) may prevent progression in MRD positive patients post-CAR T, and that a low-burden disease state may lead to favorable disease control and safety with fixed-course BsAb. This abstract reports preliminary results for the first 10 patients in the EpLCART study.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Trial: EpLCART (Phase II, multi-centre, NCT06414148).</li>
                        <li>Patient Population: LBCL pts post-commercial anti-CD19 CAR T-cell therapy, achieving PR/CMR but MRD+ between D+25 and D+100 post-infusion. ECOG ≤2, resolved CAR-T toxicities.</li>
                        <li>Intervention: 6 cycles of epcoritamab-alone or epcoritamab + lenalidomide + rituximab (epcor-R2).</li>
                        <li>ctDNA Monitoring: KAPA HyperCap DS NHL panel, ctDNAtools modified workflow.</li>
                        <li>Response Assessment: Interim PET/ctDNA after C2, EOT response after C6.</li>
                        <li>Primary Endpoint: CR by Lugano criteria at 12 months post CAR T-cell infusion.</li>
                    </ul>
                    <div class="study-design-schema">
                        <h3 class="schema-title">EpLCART Study Design (MRD-Directed Consolidation)</h3>
                        <div class="schema-enrollment">
                            <strong>LBCL Pts Post CD19 CAR-T</strong>
                            <span>PR/CMR by PET, MRD+ by ctDNA (D+25 to D+100)</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%; background-color: var(--sobi-light-blue-bg); border-color: var(--sobi-dark-blue);">
                                <strong>Intervention (6 Cycles)</strong>
                                <span>Epcoritamab-alone OR Epcoritamab + Lenalidomide + Rituximab (Epcor-R2)</span>
                            </div>
                        </div>
                        <div class="schema-assessment-points">
                           <span>Interim PET/ctDNA (Post C2)</span>
                           <span>EOT PET/ctDNA (Post C6)</span>
                           <span>Primary EP: CR at 12mo post CAR-T</span>
                           <span>Safety (CRS, ICANS, Cytopenias)</span>
                        </div>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Enrollment & Baseline (N=10)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>42 patients underwent ctDNA testing post CAR-T (Feb 5 - Nov 4, 2024).</li>
                        <li>Median ctDNA turn-around time: 12 days.</li>
                        <li>14 patients (33%) were MRD positive between D+25 and D+100.</li>
                        <li>Of MRD+ pts: 3 had PD (ineligible), 1 declined.</li>
                        <li>10 patients enrolled in EpLCART.</li>
                         <li>(Detailed baseline characteristics of the 10 enrolled patients not provided in abstract text).</li>
                    </ul>
                </div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Preliminary Results (N=10)</h2>
                    <p class="text-sm font-semibold mt-1 mb-1">Safety:</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Treatment was well-tolerated.</li>
                        <li>No Grade >1 CRS.</li>
                        <li>No ICANS.</li>
                        <li>Grade 3-4 Neutropenia: 6 patients (60%).</li>
                        <li>Grade 3-4 Thrombocytopenia: 4 patients (40%).</li>
                        <li>Clinical or microbiologically proven infections: 9.</li>
                    </ul>
                    <p class="text-sm font-semibold mt-3 mb-1">Efficacy (Interim Response Assessment Post Cycle 2):</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>MRD Negative: 8 out of 10 patients (80%).</li>
                    </ul>
                    <div class="chart-container my-4">
                        <svg id="epcartMrdResponseChart" width="300" height="250"></svg>
                        <div id="epcartMrdResponseLegend" class="legend"></div>
                    </div>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>Monitoring of ctDNA after CAR-T cell infusion is feasible, with a turn-around time allowing intervention prior to clinical progression in most cases.</li>
                <li>Epcoritamab-alone or Epcoritamab-R2 appears deliverable in the early post-CAR-T period.</li>
                <li>The treatment demonstrates a favorable toxicity profile with encouraging MRD responses.</li>
                <li>Enrollment is ongoing (target N=40), and the study is planned to open at six CAR T-cell centers in Australia.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>BsAb, Bispecific Antibody; CAR, Chimeric Antigen Receptor; CD, Cluster of Differentiation; CR, Complete Response; CRS, Cytokine Release Syndrome; ctDNA, Circulating Tumour DNA; D+, Day post-infusion; DLBCL, Diffuse Large B-cell Lymphoma; ECOG, Eastern Cooperative Oncology Group; Epcor, Epcoritamab; Epcor-R2, Epcoritamab + Lenalidomide + Rituximab; EOT, End of Treatment; FDA, Food and Drug Administration; G, Grade; ICANS, Immune-Effector Cell Associated Neurotoxicity Syndrome; KAPA, Sequencing Technology Brand; LBCL, Large B-Cell Lymphoma; MRD, Minimal Residual Disease; NCT, National Clinical Trial; NHL, Non-Hodgkin Lymphoma; PET, Positron Emission Tomography; PR, Partial Response; R/R, Relapsed and/or Refractory.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Dowling M, Inam S, Scott H, et al. Circulating tumour DNA-directed intervention with Epcoritamab alone or in combination with Lenalidomide and Rituximab is feasible in the early post-CAR-T population at high risk of relapse: Preliminary data from EpLCART. Abstract #PS1912 presented at the European Hematology Association (EHA) Congress. 12–15 June 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PS1912 | Abstract Release: 05/14/2025 | Presentation: 06/14/2025</p>
            <p>NCT06414148 | For Research & Informational Purposes Only.</p>
        </div>
    </div>

    <script defer src="abstract_features.js"></script>
    <script>
        function drawEpcartMrdResponseChart(containerId, legendContainerId) {
            const chartData = {
                keys: ["MRD Negative", "MRD Positive"],
                values: { "MRD Negative": 80.0, "MRD Positive": 20.0 }, // 8/10 MRD neg, so 2/10 MRD pos
                colors: ["var(--sobi-teal)", "var(--sobi-orange)"]
            };
            const chartTitle = "MRD Status Post Cycle 2 (N=10)";

            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);

            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 300;
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.8, 200);
            }

            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height");
            const margin = { top: 40, right: 20, bottom: 20, left: 20 };
            const radius = Math.min(svgWidth - margin.left - margin.right, svgHeight - margin.top - margin.bottom) / 2;

            const g = svg.append("g")
                .attr("transform", `translate(${svgWidth/2}, ${(svgHeight/2) + margin.top/2 - 10})`);

            const pie = d3.pie().sort(null).value(d => d.value);
            const path = d3.arc().outerRadius(radius - 10).innerRadius(0);
            const label = d3.arc().outerRadius(radius).innerRadius(radius - 30);

            const arcs = g.selectAll(".arc")
                .data(pie(chartData.keys.map(key => ({ key: key, value: chartData.values[key], color: chartData.colors[chartData.keys.indexOf(key)] }))))
                .enter().append("g")
                .attr("class", "arc");

            arcs.append("path")
                .attr("d", path)
                .attr("fill", d => d.data.color);

            arcs.append("text")
                .attr("transform", d => `translate(${label.centroid(d)})`)
                .attr("dy", "0.35em")
                .style("font-size", "10px")
                .style("text-anchor", "middle")
                .style("fill", d => (d.data.key === "MRD Negative") ? "white" : "var(--sobi-dark-text)")
                .text(d => `${d.data.value.toFixed(0)}%`);

            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", margin.top / 2 + 5)
                .attr("text-anchor", "middle")
                .style("font-size", "13px")
                .style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)")
                .text(chartTitle);

            const legendData = chartData.keys.map(key => ({
                label: `${key} (${chartData.values[key].toFixed(0)}%)`,
                color: chartData.colors[chartData.keys.indexOf(key)]
            }));

            const legendItems = legendContainer.selectAll(".legend-item")
                .data(legendData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.label);
        }

        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => { clearTimeout(timeout); func(...args); };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawChart = debounce(() => drawEpcartMrdResponseChart("#epcartMrdResponseChart", "#epcartMrdResponseLegend"), 250);

        window.addEventListener('resize', debouncedDrawChart);
        document.addEventListener('DOMContentLoaded', debouncedDrawChart);
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(debouncedDrawChart, 0);
        }
    </script>
</body>
</html>